Curated News
By: NewsRamp Editorial Staff
September 29, 2026
GeoVax Highlights CDC Report on Sustained Clade Ib Mpox Transmission in U.S.
TLDR
- GeoVax advances GEO-MVA, a potential second MVA vaccine, directly to Phase 3, aiming to capture diversified government supply contracts.
- GeoVax's GEO-MVA skips Phase 1 and 2 under EMA guidance, starting a 500-participant Phase 3 immunobridging trial in Q4 2026.
- GeoVax's GEO-MVA aims to expand global MVA vaccine access, strengthening preparedness against mpox and protecting at-risk communities worldwide.
- CDC reports Clade Ib mpox domestic transmission in over 10 U.S. jurisdictions, signaling a shift from travel-linked cases to sustained local spread.
Impact - Why it Matters
The CDC's confirmation of likely sustained Clade Ib mpox transmission in the United States marks a pivotal shift in the virus's epidemiology, moving beyond travel-associated cases to domestic spread. This development matters because it signals that mpox is becoming an endemic threat, requiring robust public health infrastructure and vaccine readiness. GeoVax's accelerated development of GEO-MVA, with a pivotal Phase 3 trial set to begin in late 2026, could provide a critical additional vaccine option, enhancing supply resilience and biosecurity. As infectious diseases continue to cross borders, proactive measures—such as diversified vaccine supply and scalable manufacturing—are essential to protect at-risk populations and prevent future crises. This news underscores the need for sustained investment in preparedness, not just reaction, to safeguard global health.
Summary
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, has highlighted a significant shift in the U.S. epidemiology of Clade I mpox, as reported by the U.S. Centers for Disease Control and Prevention (CDC). In its September 25 update, the CDC confirmed over 60 laboratory-confirmed Clade I mpox cases across at least 20 states, with an increasing proportion of cases occurring among individuals with no recent international travel or known links to travelers. Presumed domestic transmission has been reported in more than 10 jurisdictions, leading the CDC to indicate a 'likely transition to sustained Clade Ib transmission in the United States.' While the risk to the general population remains low, the agency expects additional travel-related and domestically acquired cases.
David Dodd, Chairman and CEO of GeoVax, emphasized that this development underscores the importance of continued surveillance, vaccination of at-risk populations, and sustained preparedness. He stated, 'Preparedness should not begin when an infectious-disease threat becomes a crisis. The appropriate time to strengthen vaccine capacity, diversify sources of supply and establish scalable manufacturing infrastructure is before those capabilities are urgently needed.' GeoVax is advancing GEO-MVA, its Modified Vaccinia Ankara (MVA)-based vaccine for mpox and smallpox, through an expedited clinical development pathway. Following formal guidance from the European Medicines Agency, the company plans to initiate a pivotal Phase 3 immunobridging study in the fourth quarter of 2026, with results expected in mid-2027. The study will compare immune responses generated by GEO-MVA with those of the licensed MVA-BN comparator. GeoVax believes GEO-MVA can become a strategic preparedness asset by supporting diversified vaccine supply and scalable manufacturing capacity.
The changing mpox landscape is particularly noteworthy because the 2022 global outbreak was caused by Clade IIb, while Clade I has historically been associated with more severe disease. However, recent Clade Ib cases in high-income countries have generally involved milder illness. The CDC's assessment represents an evolution from earlier surveillance, as sustained Clade Ib transmission had not been detected in the U.S. during 2024–2025. Globally, Clade I outbreaks have continued in Central and Eastern Africa since late 2023, with geographic expansion to Europe and the United States. For more information, visit www.geovax.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, GeoVax Highlights CDC Report on Sustained Clade Ib Mpox Transmission in U.S.
